Skip to main content

Market Overview

Cellectar Biosciences Jumps 200% After Getting Patent Identification Numbers For Cancer-Targeting Drug Vehicles


Cellectar Biosciences, Inc. (NASDAQ: CLRB), an oncology-focused biotechnology company, revealed Friday that it got patent identification numbers for its Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles. The company has filed non-provisional US and International patent applications earlier. According to the company, it marked the next step in the application process for approval, as well as, issuance of these patents.

The company's President and CEO, Jim Caruso, commented "When issued, these patents will provide Cellectar and potential partners with intellectual property (IP) protection through approximately November 2036, providing significant runway for product development and commercialization. This expanded IP protection supports the value-optimizing potential of our CLR CTX chemotherapeutic program and we look forward to providing ongoing updates as we continue to advance this R&D program."

Cellectar Biosciences said that these patents would protect both composition of matter and method of use for those phospholipid drug conjugates, or PDCs, developed with its proprietary phospholipid-ether delivery vehicle conjugated with any existing or future cytotoxic agents. It included chemotherapeutics like paclitaxel, for targeted delivery to cancer cells and cancer stem cells.

Following the news, the stock jumped 190 percent on Friday.


Related Articles (CLRB)

View Comments and Join the Discussion!

Posted-In: Biotech News General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at